國立高雄大學圖資館 |

Language: English

Back

Alzheimer's disease drug developmentresearch and development ecosystem /

Record Type:	Electronic resources : Monograph/item
Title/Author:	Alzheimer's disease drug developmentedited by Jeffrey Cummings, Jefferson Kinney, Howard Fillit.
Reminder of title:	research and development ecosystem /
other author:	Cummings, Jeffrey L.
Published:	Cambridge :Cambridge University Press,2022.
Description:	xx, 554 p. :ill., digital ;26 cm.
Notes:	Title from publisher's bibliographic system (viewed on 07 Mar 2022).
Subject:	Alzheimer's disease.
Online resource:	https://doi.org/10.1017/9781108975759
ISBN:	9781108975759$q(electronic bk.)

Alzheimer's disease drug developmentresearch and development ecosystem /
Alzheimer's disease drug developmentresearch and development ecosystem /[electronic resource] :edited by Jeffrey Cummings, Jefferson Kinney, Howard Fillit. - Cambridge :Cambridge University Press,2022. - xx, 554 p. :ill., digital ;26 cm. - Cambridge medicine. - Cambridge medicine (Series).

Title from publisher's bibliographic system (viewed on 07 Mar 2022).

Alzheimer's Disease (AD) is a growing global public health challenge. The development of new therapies is urgently needed, and a complex ecosystem of organizations has grown to facilitate AD drug discovery and development. Masterfully collating information on the drug development ecosystem, this book emphasizes the contributions of each aspect in the pipeline with a uniform approach to chapters, enabling readers to access relevant information quickly. Topics covered include the use of non-clinical laboratory studies, biomarker development, artificial intelligence, design and management of clinical trials, and funding and financing models. Also discussed is the critical role of advocacy fundraising for drug development. With the approval of aducanumab, the function of the ecosystem has become apparent. This is a definitive overview of how the ecosystem works in transferring an AD drug from its discovery in the laboratory through clinical trial testing to regulatory review and eventual marketing.

ISBN: 9781108975759$q(electronic bk.)Subjects--Topical Terms:

229397
Alzheimer's disease.

LC Class. No.: RC523 / .A3975964 2022

Dewey Class. No.: 616.831

Alzheimer's disease drug developmentresearch and development ecosystem /
LDR:01914nmm a2200253 a 4500 001 626741
003 UkCbUP
005 20220314063149.0
006 m d
007 cr nn 008maaau
008 230118s2022 enk o 1 0 eng d
020 $a 9781108975759$q(electronic bk.)
020 $a 9781108838665$q(hardback)
035 $a CR9781108975759
040 $a UkCbUP $b eng $c UkCbUP $d GP
050 0 0 $a RC523 $b .A3975964 2022
082 0 0 $a 616.831 $2 23
090 $a RC523 $b .A478 2022
245 0 0 $a Alzheimer's disease drug development $h [electronic resource] : $b research and development ecosystem / $c edited by Jeffrey Cummings, Jefferson Kinney, Howard Fillit.
260 $a Cambridge : $b Cambridge University Press, $c 2022.
300 $a xx, 554 p. : $b ill., digital ; $c 26 cm.
490 1 $a Cambridge medicine
500 $a Title from publisher's bibliographic system (viewed on 07 Mar 2022).
520 $a Alzheimer's Disease (AD) is a growing global public health challenge. The development of new therapies is urgently needed, and a complex ecosystem of organizations has grown to facilitate AD drug discovery and development. Masterfully collating information on the drug development ecosystem, this book emphasizes the contributions of each aspect in the pipeline with a uniform approach to chapters, enabling readers to access relevant information quickly. Topics covered include the use of non-clinical laboratory studies, biomarker development, artificial intelligence, design and management of clinical trials, and funding and financing models. Also discussed is the critical role of advocacy fundraising for drug development. With the approval of aducanumab, the function of the ecosystem has become apparent. This is a definitive overview of how the ecosystem works in transferring an AD drug from its discovery in the laboratory through clinical trial testing to regulatory review and eventual marketing.
650 0 $a Alzheimer's disease. $3 229397
650 0 $a Alzheimer's disease $x Treatment. $3 188756
650 0 $a Drugs $x Research. $3 184201
650 0 $a Drug development. $3 190608
700 1 $a Cummings, Jeffrey L. $3 930401
700 1 $a Fillit, Howard. $3 930402
700 1 $a Kinney, Jefferson W. $3 930403
830 0 $a Cambridge medicine (Series) $3 898692
856 4 0 $u https://doi.org/10.1017/9781108975759